New influenza treatment found to reduce spread of virus


Tuesday, 21 April, 2020


New influenza treatment found to reduce spread of virus

Australian and UK researchers have shown that a new antiviral drug for influenza can treat the infection at the same time as reducing the risk of transmission to others, offering the potential to change the way we manage influenza outbreaks — particularly in vulnerable groups.

The antiviral drug, baloxavir (tradename Xofluza), is said to be the first treatment for influenza with a new mode of ‘action’ to be licensed in nearly 20 years. It was approved in Australia in February 2020 by the Therapeutic Goods Administration (TGA) and has been used to treat influenza in Japan, the US and several other countries since 2018.

Researchers at the WHO Collaborating Centre for Reference and Research on Influenza at Melbourne’s Peter Doherty Institute for Infection and Immunity and Imperial College London tested whether baloxavir could prevent the spread of influenza virus in an animal model in conditions that mimicked household settings, including direct and indirect contact. They also compared the treatment to oseltamivir (tradename Tamiflu), a widely prescribed influenza antiviral. Their study was conducted in ferrets — considered the gold standard animal model for evaluating influenza — and published in the journal PLOS Pathogens.

The study found that baloxavir reduced the transmission of influenza across all settings, and did so immediately. Conversely, oseltamivir did not reduce the transmission of influenza to other ferrets. First author Leo Yi Yang Lee, a medical scientist at the WHO Collaborating Centre for Reference and Research on Influenza, believes the results are an important breakthrough in our understanding of managing the influenza virus.

“Our research provides evidence that baloxavir can have a dramatic dual effect: a single dose reduces the length of influenza illness, while simultaneously reducing the chance of passing it on to others,” Lee said.

“This is very important, because current antiviral drugs only treat influenza illness in the infected patient. If you want to reduce the spread of influenza to others, people in close contact need to take antiviral drugs themselves to stave off infection.”

Senior author Professor Wendy Barclay, from Imperial College London, said if the results of the study were replicated in humans, the discovery could be a game changer in stemming outbreaks of influenza, particularly amongst vulnerable groups.

“We know that influenza can have serious and devastating outcomes for people with compromised immune systems, such as those in care facilities and hospitals, where finding more ways to reduce transmission is essential,” Prof Barclay said.

A clinical trial is currently underway to test the effectiveness of baloxavir in reducing transmission amongst human household contacts by treating individuals infected with influenza and monitoring for infection in household members. Prof Barclay said, “If further trials prove successful, baloxavir could dramatically change how we manage seasonal influenza outbreaks and pandemic influenza in the future.”

Image credit: ©stock.adobe.com/au/RioPatuca Images

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.

Related News

Brainwaves can predict future pain sensitivity

Scientists have demonstrated that one particularly prevalent pattern of brain activity, called...

REM sleep regulates eating behaviour

Electrical activity in hypothalamic circuits during REM sleep is essential to maintain a stable...

High BMI negatively impacts brain function

Being overweight or obese seriously impacts brain activity and increases the risk for...


  • All content Copyright © 2020 Westwick-Farrow Pty Ltd